Arcutis Presents Patient-Reported Outcome Data From The Pivotal ARRECTOR Phase 3 Trial In Scalp And Body Psoriasis At European Academy Of Dermatology And Venereology Congress
Portfolio Pulse from Benzinga Newsdesk
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has presented new data from its ARRECTOR Phase 3 trial of roflumilast foam 0.3% for the treatment of adults and adolescents with scalp and body psoriasis. The data shows significant improvements in both scalp and body psoriasis across all efficacy endpoints compared to vehicle. The results were presented at the EADV Congress held in Berlin. The company's Chief Medical Officer, Patrick Burnett, stated that the data suggests roflumilast foam may be an important topical treatment option.
October 13, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcutis Biotherapeutics has presented positive data from its Phase 3 trial of roflumilast foam for psoriasis treatment, which could potentially boost the company's stock.
The positive results from the Phase 3 trial of roflumilast foam for psoriasis treatment could potentially lead to regulatory approval and commercialization of the product, which would likely have a positive impact on the company's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100